WHETHER PRIMARY TUMOR LOCALIZATION IS IMPORTANT FOR THE PREDICTION OF DRUG TREATMENT OF METASTATIC COLON CANCER?


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The effectiveness of the treatment of metastatic colorectal cancer was significantly improved by the introduction of monoclonal antibodies to vascular endothelial growth factors and epidermal growth factors into clinical practice. Currently, there are reports about the various efficacy of treatment of metastases of the primary tumor of the right and left parts of the colon. The data presented in the review allows to rationalize the use of monoclonal antibodies taking into account the localization of the primary tumor. It is shown that in the «targeted» population anti-VEGF-agents provide significant advantage in terms of survival in case of localization of tumors in the right segment, and anti-EGFR-agents - in case of localization of tumors in the left segment.

Full Text

Restricted Access

About the authors

N. V Dobrova

Email: dobrova2008@rambler.ru
FSBI RORC n.a. N.N. Blokhin of RMH PhD, Senior Researcher at the Department of Chemotherapy and Combined Therapy of Malignant Tumors Moscow

E. I Borisova

FSBI RORC n.a. N.N. Blokhin of RMH Moscow

S. L Gutorov

FSBI RORC n.a. N.N. Blokhin of RMH Moscow

M. E Abramov

FSBI RORC n.a. N.N. Blokhin of RMH Moscow

References

  1. Fleming M., Ravula S., Tatishchev S.F., Wang H.L. Colorectal carcinoma: pathologic aspects. J. Gastrointest. Oncol. 2012;3:153- 73.
  2. Hawkins N.J., Tomlinson I., Meagher A., Ward R.L. Microsatellite-stable diploid carcinoma: a biologically distinct and aggressive subset of sporadic colorectal cancer. Br. J. Cancer. 2001;84:232-36.
  3. Russo A., Bazan V., Iacopetta B., Kerr D., Soussi T., Gebbia N. The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment. J. Clin. Oncol. 2005;23:7518-28.
  4. Nasir A., Kaiser H.E., Boulware D., Hakam A., Zhao H., Yeatman T., et al. Barthel J, Coppola D. Cyclooxygenase-2 expression in right- and leftsided colon cancer: a rationale for optimization of cyclooxygenase-2 inhibitor therapy. Clin. Colorectal Cancer. 2004;3:243-47.
  5. Watatani M., Yoshida T., Kuroda K., Ieda S., Yasutomi M. Allelic loss of chromosome 17p, mutation of the p53 gene, and microsatellite instability in right- and left-sided colorectal cancer. Cancer. 1996;77:1688-93.
  6. Markowitz S.D., Bertagnolli M.M. Molecular origins of cancer: molecular basis of colorectal cancer. N Engl J Med. 2009;361:2449-60.
  7. Jacobs B., De Roock W., Piessevaux H., Van Oirbeek R., Biesmans B., De Schutter J., Fieuws S., Vandesompele J., Peeters M., Van Laethem J.-L., Humblet Y., P'enault-Llorca F., De Hertogh G., Laurent-Puig P., Van Cutsem E., Tejpar S. Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab. J. Clin. Oncol. 2009;27:5068-74.
  8. Pai R.K., Jayachandran P., Koong A.C., Chang D.T., Kwok S., Ma L., Arber D.A., Balise R.R., Tubbs R.R., Shadrach B. BRAF-mutated, microsatellite-stable adenocarcinoma of the proximal colon: an aggressive adenocarcinoma with poor survival, mucinous differentiation, and adverse morphologic features. Am. J. Surg. Pathol. 2012;36:744-52.
  9. Popovici V., Budinska E., Bosman F.T., Tejpar S., Roth A.D., Delorenzi M. Context-dependent interpretation of the prognostic value of BRAF and KRAS mutations in colorectal cancer. BMC Cancer. 2013;13:439.
  10. Grimminger P.P., Shi M., Barrett C. TS and ERCC-1 mRNA expressions and clinical outcome in patients with metastatic colon cancer in CONFIRM-1 and -2 clinical trials. Pharmacogenomics J. 2012;12: 404-13.
  11. Scartozzi M., Bearzi I., Mandolesi A., Giampier R., Faloppi L., Galizia E., Loupakis F., Zaniboni A., Zorzi F., Biscotti T., Labianca R., Falcone A., Cascinu S. Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patients. Br. J. Cancer. 2011;104:1786-90.
  12. Guinney J., Dienstmann R., Wang X., de Reynies A., Schlicker A., Soneson C., Marisa L., Roepman P., Nyamundanda G., Angelino P., Bot B.M., Morris J.S., Simon I.M., Gerster S., Fessler E., DeSousa E., Melo F., Missiaglia E., Ramay H., Barras D., Homicsko K., Maru D., Manyam G.C., Broom B., Boige V., Perez-Villamil B., Laderas T., Salazar R., Gray J.W., Hanahan D., Tabernero J., Bernards R., Friend S.H., Laurent-Puig P., Medema J.P., Sadanandam A., Wessels L., Delorenzi M., Kopetz S., Vermeulen L., Tejpar S. The consensus molecular subtypes of colorectal cancer. Nat Med 2015;21:1350-56.
  13. Iacopetta B. Are there two sides to colorectal cancer? int. J. Cancer. 2002;101:403-8.
  14. Lindblom A. Different mechanisms in the tumorigenesis of proximal and distal colon cancers. Curr. Opin. Oncol. 2001;13:63-9.
  15. von Einem J.C., Heinemann V., Fischer von Weikersthal L., Vehling-Kaiser U., Stauch M., Hass H.G., Decker T., Klein S., Held S., Jung A., Kirchner T., Haas M., Holch J., Michl M., Aubele P., Boeck S., Schulz C., Giessen C., Stintzing S., Modest D.P. Leftsided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild type metastatic colorectal cancer treated with cetuximab plus chemotherapy:an analysis of the AiO KRK 0104 trial. J. Cancer Res. Clin. Oncol. 2014;140:1607-14.
  16. Missiaglia E., Jacobs B., Di Narzo A.F., Soneson C., Roth А., Bosman F., d'Ario G., Klingbiel D., Yan P., Delorenzi M., Tejpar S. Proximal and distal colon tumors as distinct biologic entities with different prognoses. J. Clin. Oncol. 2013;31(suppl; abstr 3526). epub 2013 ASCO annual Meeting.
  17. Brulé S.Y., Jonker D.J., Karapetis C.S., O'Callaghan C.J., Moore M.J., Wong R., Tebbutt N.C., Underhill Cr., Yip D., Zalcberg C.J., Tu D., Goodwin R.A. Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCiC CO.17 EJS. 2015;51(issue 11):1405-14.
  18. Moretto R., Cremolini C., Rossini D., Pietrantonio F., Battaglin F., Mennitto A., Bergamo F., Loupakis F., Marmorino F., Berenato R., Valentina Angela Marsico V.A., Caporale M., Antoniotti C., Masi G., Salvatore L., Borelli B., Fontanini G., Lonardi S., De Braud F., Falcone A. Location of Primary Tumor and Benefit From Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer. Oncologist. 2016;21:1-7.
  19. Wang F., Bai L., Liu T.-S., Yu Y.-Y., He M.-M., Liu K.-Y., Luo H.-Y., Zhang D.-S., Jin Y., Wang F.-H., Wang Z.-Q., Wang D.-S., Qiu M.-Z., Ren C., Li Y.-H., Xu R.-H. Right- and left-sided colorectal cancers respond differently to cetuximab. Chinese J. Cancer. 2015;34:24.
  20. Brule S.Y., Jonker D.J., Karapetis C.S., O'Callaghan C.J., Moore M.J., Wong R., Tebbutt N.C., Underhill Cr., Yip D., Zalcberg C.J., Tu D., Goodwin R.A. Location of colon cancer (right-sided [RC] versus left-sided [LC]) as a predictor of benefit from cetuximab (CET): NCiC CTG CO.17. J. Clin. Oncol. 2013;31:3528.
  21. Elsaleh H., Joseph D., Grieu F., Zeps N., Spry N., Iacopetta B. Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer. Lancet. 2000;355:1745-50.
  22. Boisen M.K., Johansen J.S., Dehlendorff C., Larsen J.S., 0sterlind K., Hansen J., Nielsen S. E., Pfeiffer P., Tarpgaard L.S., Holländer N.H., Keldsen N., Hansen T.F., Jensen B.B., Jensen B.V. Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer. Ann. Oncol. 2013;24:2554-59.
  23. Venook A.P., Niedzwiecki D., Innocenti F., Fruth D., Greene C., O'Neil B.H., Shaw J.E., Atkins J.N., Horvath L.E., Polite B.N., Meyerhardt J.A., O'Reilly E.M., Goldberg R.M., Hochster H.S., Blanke C.D., Schilsky R.L., Mayer R.J., Bertagnolli M.M., Lenz H.-J. impact of primary (1o) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): analysis of CALGB/SWOG 80405 (Alliance). J. Clin. Oncol. 2016;(suppl; abstr 3504).
  24. Mais L., Bourien H., Aboudaram A., Lièvre A., Dupuy M., Francois E., Artru P., Senellart H., Coriat R., Edeline J., Guimbaud R., Samalin E., Desseigne F., Sarabi M., Guibert P., Ferlay C., De La Fouchardiere C. Analysis of medical practices for French patients with BRAF mutant metastatic colorectal cancer. J. Clin. Oncol. 2016;34(suppl; abstr e15070).

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2016 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies